Diagnosis and Management of Adult Central Nervous System Leukemia

Overview

Journal Blood Sci

Date 2023 Aug 7

PMID 37546706

Authors

Siyu Liu

Ying Wang

Affiliations

Soon will be listed here.

Abstract

Central nervous system leukemia (CNSL) is a prominent infiltration reason for therapy failing in acute leukemia. Recurrence rates and the prognosis have alleviated with current prophylactic regimens. However, the accurate stratification of relapse risk and treatment regimens for relapsed or refractory patients remain clinical challenges yet to be solved. Recently, with hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) cellular therapy showing encouraging effects in some CNSL patients, advances in treating CNSL have already been reported. The development of molecular targeted agents as well as antibody-based drugs will provide patients with more personalized treatment. This article summarized recent research developments about risk factors, diagnosis, prevention, and treatment in adults with CNSL.

Citing Articles

Clinical data and MRI features-based nomogram for differentiation of central nervous system infection and central nervous system involvement in hematological malignancy.

Yi H, Ren Y, Zhang S, Xu C, Yang W, Chen X Ann Hematol. 2024; 103(12):5915-5923.

PMID: 39407036 DOI: 10.1007/s00277-024-06036-9.

Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients.

Jian Y, Han F, Zhu Y, Geng C, Zhang Y, Wu Y Clin Transl Sci. 2024; 17(9):e70006.

PMID: 39286959 PMC: 11406145. DOI: 10.1111/cts.70006.

References

Xi X, Zong Y, Ji Y, Wang B, Liu H . Experiment research of focused ultrasound combined with drug and microbubble for treatment of central nervous system leukemia. Oncotarget. 2018; 9(4):5424-5434. PMC: 5797061. DOI: 10.18632/oncotarget.23521. View

McClune B, Buadi F, Aslam N, Przepiorka D . Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphoma. Leuk Lymphoma. 2007; 48(9):1849-51. DOI: 10.1080/10428190701573232. View

Chen X, Huang J, Xu N, Fan Z, Nie D, Huang F . A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia. Cancer. 2022; 128(11):2138-2147. DOI: 10.1002/cncr.34182. View

Pui C . Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program. 2006; :142-6. DOI: 10.1182/asheducation-2006.1.142. View

Del Principe M, Buccisano F, Soddu S, Maurillo L, Cefalo M, Piciocchi A . Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. Semin Hematol. 2018; 55(4):209-214. DOI: 10.1053/j.seminhematol.2018.02.006. View

Bueno C, Velasco-Hernandez T, Gutierrez-Aguera F, Zanetti S, Baroni M, Sanchez-Martinez D . CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia. 2019; 33(8):2090-2125. PMC: 6756031. DOI: 10.1038/s41375-019-0418-8. View

Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R . Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112(4):1005-12. DOI: 10.1182/blood-2008-02-140665. View

Rocha J, Cheng C, Liu W, Kishi S, Das S, Cook E . Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood. 2005; 105(12):4752-8. PMC: 1895006. DOI: 10.1182/blood-2004-11-4544. View

Zhang X, Lu X, Yang J, Zhang G, Li J, Song L . Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features. Blood Adv. 2020; 4(10):2325-2338. PMC: 7252549. DOI: 10.1182/bloodadvances.2020001466. View

10.

Tachibana T, Najima Y, Akahoshi Y, Hirabayashi S, Harada K, Doki N . The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. Ann Hematol. 2020; 99(10):2393-2404. DOI: 10.1007/s00277-020-04212-1. View

11.

Naydenov A, Taylor L . Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature. Oncologist. 2019; 24(9):1237-1245. PMC: 6738317. DOI: 10.1634/theoncologist.2018-0619. View

12.

Reda G, Cassin R, Dovrtelova G, Matteo C, Giannotta J, DIncalci M . Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. 2019; 104(5):e222-e223. PMC: 6518888. DOI: 10.3324/haematol.2018.213157. View

13.

Larson R . Managing CNS disease in adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2017; 59(1):3-13. DOI: 10.1080/10428194.2017.1326597. View

14.

de Souza S, Santiago F, Ribeiro-Carvalho M, Arnobio A, Soares A, Ornellas M . Leptomeningeal involvement in B-cell chronic lymphocytic leukemia: a case report and review of the literature. BMC Res Notes. 2014; 7:645. PMC: 4246480. DOI: 10.1186/1756-0500-7-645. View

15.

Aldoss I, Al Malki M, Stiller T, Cao T, Sanchez J, Palmer J . Implications and Management of Central Nervous System Involvement before Allogeneic Hematopoietic Cell Transplantation in Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2015; 22(3):575-8. DOI: 10.1016/j.bbmt.2015.10.016. View

16.

Bromberg J, van der Meulen M, Doorduijn J . The Role of Rituximab in Primary Central Nervous System Lymphoma. Curr Oncol Rep. 2020; 22(8):78. PMC: 7324418. DOI: 10.1007/s11912-020-00941-8. View

17.

Chen Q, Zhu X, Zhao X, Liu X, Fu H, Zhang Y . Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Ann Hematol. 2021; 100(2):505-516. DOI: 10.1007/s00277-020-04380-0. View

18.

Sancho J, Ribera J, Oriol A, Hernandez-Rivas J, Rivas C, Bethencourt C . Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006; 106(12):2540-6. DOI: 10.1002/cncr.21948. View

19.

Parker J, Mays K, Pratibhu P, Pick P, Block D . Optic Perineuritis Presenting as the Initial Manifestation of Central Nervous System Involvement in Rai Stage 0 Chronic Lymphocytic Leukemia. J Neuroophthalmol. 2022; 42(1):e187-e191. DOI: 10.1097/WNO.0000000000001263. View

20.

Dhillon S . Olverembatinib: First Approval. Drugs. 2022; 82(4):469-475. DOI: 10.1007/s40265-022-01680-9. View